Menu Search
Equities

Abcellera Biologics Inc

8QQ:MUN

Abcellera Biologics Inc

Actions
  • Price (EUR)2.47
  • Today's Change-0.080 / -3.15%
  • Shares traded390.00
  • 1 Year change-39.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Abcellera Biologics Inc's revenues fell -92.17% from 485.42m to 38.03m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 158.52m to a loss of 146.40m.
Gross margin--
Net profit margin-533.32%
Operating margin-934.58%
Return on assets-12.10%
Return on equity-15.55%
Return on investment-12.95%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Abcellera Biologics Inc fell by 254.04m. Cash Flow from Financing totalled 10.36m or 27.23% of revenues. In addition the company used 43.88m for operations while cash used for investing totalled 221.11m.
Cash flow per share-0.307
Price/Cash flow per share--
Book value per share3.71
Tangible book value per share3.36
More ▼

Balance sheet in USDView more

Abcellera Biologics Inc uses little or no debt in its capital structure.
Current ratio9.34
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.